Concept
- Histapharm’s concept is to degrade histamine in the lumen of the gut by giving orally the enzyme DAO associated with Catalase and having as result an equilibrated histamine level.
- The concept is based on the natural mechanism occurring in healthy subjects where the enzyme DAO is degrading histamine. By mimicking body physiology, we are introducing a therapeutic approach that can balance histamine excess and solve many related dysfunctions.
- The novelty of the concept is the association of vegetal DAO to Catalase with the aim to eliminate the prooxidant hydrogen peroxide by-product and to generate in situ supplementary oxygen favoring the histamine degradation.
- The concept was first introduced by our group starting with 2012 and published in various scientific journals or under patent form: Calinescu et al, 2012; Jumarie et al., 2017;
- US 9 878 020 B2 https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9878020;
- EP 2 694 098 B1 https://data.epo.org/publication-server/document?iDocId=5715741&iFormat=0;
- CA 2 831 535 https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2831535/summary.html?query=oral+composition+for+intestinal&type=basic_search